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Introduction
Colorectal cancer (CRC) is the second most commonly 
diagnosed cancer in females and the third most commonly 
diagnosed cancer in males globally (Ferlay et al., 2015). 
Epidemiological studies indicate that the incidence and 
mortality due to CRC vary with the highest incidence 
of CRC reported in developed countries, but a higher 
mortality in the developing ones (Ferlay et al., 2015). A 
peak increase in incidence has been noted in economically 
transitioning countries (Center et al., 2009). This leads to 
the hypothesis that increase in CRC can be attributed to 
the environmental and dietary factors superimposed on 
genetic predisposition.
Age is one of the major risk factors for colon cancer 
with as many as 90% of cases being diagnosed in patients 
above 50 years of age (Jemal et al., 2010). Diagnosis 
under the age of 40-50 years is uncommon. Thereafter, the 
incidence increases sharply with each decade of life. An 
analysis by the Karachi Cancer Registry found Pakistan 
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Abstract
 Background: Early onset sporadic colorectal cancer (CRC) is a biologically and clinically distinct entity 
hypothesized to exhibit differences in histological features and microsatellite instability (MSI) as compared to 
typical onset CRC. This study compared the MSI status, mismatch repair enzyme deficiency and clinicopathological 
features of early onset (aged ≤45 years) with controls (>45 years). Materials and Methods: A total of 30 cases and 
30 controls were analyzed for MSI status using the Bethesda marker panel. Using antibodies against hMLH1, 
hMSH2 and hMSH6, mismatch repair protein expression was assessed by immunohistochemistry. Molecular 
characteristics were correlated with clinicopathological features. Results: The early onset sporadic CRCs were 
significantly more poorly differentiated tumors, with higher N2 nodal involvement and greater frequency of 
signet ring phenotype than the typical onset cases. MSI was observed in 18/30 cases, with 12/18 designated as 
MSI-high (MSI-H) and 6/18 designated as MSI-low (MSI-L). In the control group, 14 patients exhibited MSI, 
with 7 MSI-H and 7 MSI-L. MSI tumors in both cases and controls exhibited loss of hMLH1, hMSH2 and 
hMSH6. MSS tumors did not exhibit loss of expression of MMR proteins, except hMLH1 protein in 3 controls. 
No statistically significant difference was noted in MSI status or expression of MMR proteins in cases versus 
controls. Conclusions: Microsatellite status is comparable between early and typical onset sporadic CRC patients 
in Pakistan suggesting that differences in clinicopathological features between these two subsets are attributable 
to other molecular mechanisms. 
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to be a low risk region with a crude incidence rate of 
3.2 – 4.5% (Bhurgri et al., 2011). However, the ratio of 
patients diagnosed under the age of 40-50 years is much 
higher than the international average. While early onset 
cases account for only 7% of CRCs in more developed 
countries (O’Connell et al., 2004), they account for ~50% 
of cases in Pakistan (Bhurgri et al., 2011). The reason for 
this difference is yet to be elucidated.
Early onset of CRC is often attributable to a hereditary 
component, with Lynch syndrome being the most common 
hereditary form. This syndrome is characterized by 
germline mutations in DNA mismatch repair (MMR) 
genes, such as hMLH1, hMSH2, hMSH6, and hPMS2 
(Peltomäki, 2005) that lead to changes in length of DNA 
fragments known as microsatellite instability (MSI) 
(Boland, 2005). However, 10% to 15% of sporadic tumors 
also exhibit MSI (Yoon et al., 2011). 
In 1997, the National Cancer Institute validated a five 
marker panel for determination of MSI. This Bethesda 
marker panel includes two mononucleotide markers; 
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BAT25 and BAT26, and three dinucleotide markers; 
D5S346, D2S123 and D17S250 (Boland et al., 1998). 
Using this panel, a tumor is designated MSI high (MSI-H) 
if instability is observed in 30% or more of the five 
markers. Cases are designated as MSI low (MSI-L) and 
microsatellite stable (MSS) if less than 30% or no marker 
instability is found, respectively (Boland et al., 1998).
It has been hypothesized that early onset sporadic 
colon cancer is a biologically and clinically distinct 
entity from typical onset sporadic colon cancer. Given the 
noted increased incidence of early onset CRC patients in 
Pakistan, we compared the clinicopathological features 
and molecular characteristics, including microsatellite 
instability, of sporadic early onset and typical onset colon 
cancer cases in Pakistan.
Materials and Methods
Subjects: This was a single center retrospective case-
control study approved by the institutional Ethical Review 
Committee. Cases and controls were defined as patients 
45 years or younger and older than 45 years, respectively. 
Medical records and clinical details spanning 2003 – 
2011 were reviewed for patients who had undergone 
surgical resection of histologically verified primary 
adenocarcinoma of the colon and rectum at The Aga Khan 
University Hospital in Karachi, Pakistan. Clinical data for 
131 patients was retrieved, the details of which have been 
published previously (Zahir et al., 2014). Of this cohort, 
a total of 30 subjects each were selected for the case 
and control group depending on the following inclusion 
criteria: patients ≤45 years of age (cases) or >45 years 
(controls), without family history of CRC or suspicion 
of Lynch syndrome or inflammatory bowel syndrome, 
and enough tumor and adjacent normal tissue samples for 
molecular and immunohistochemical analysis. Formalin 
fixed paraffin embedded (FFPE) blocks of identified and 
consented cases and controls were obtained from the 
Department of Pathology and Laboratory Medicine. 
Histopathologic assessment: Sections from the 
selected FFPE blocks were reviewed by histopathologists 
and assessed for tumor location, grade and histological 
sub-type. Tumors located before the splenic flexure were 
considered as right-sided.
Immunohistochemical analysis: For each case, a 
single FFPE block with tumor tissue and normal colonic 
tissue was selected for the detection of hMLH1, hMSH2 
and hMSH6 proteins. In cases where normal and tumor 
tissue were not available in the same block, two separate 
blocks from the same patient were utilized. Tissue sections 
of 4μm thickness were incubated with concentrated 
monoclonal mouse anti-human antibodies against hMLH1 
and hMSH2 and monoclonal rabbit anti-human antibody 
against hMSH6 (Dako, Denmark; dilutions 1:50, 1:600 
and 1:100, respectively) on Dako Autostainer Link 
48 (Agilent Technologies Company, Denmark) using 
EnVisionFLEX kit (Dako, Denmark). A positive reaction 
showed unequivocal nuclear staining of normal epithelial 
cells and neoplastic cells. Tumor cells without nuclear 
staining in the presence of a positive internal control were 
considered deficient for the antigen.
MSI analysis: For MSI analysis, histopathologists 
identified and marked areas with normal and tumor content 
on the relevant FFPE blocks. After micro-dissection, 
DNA was extracted from tumor tissue and from normal 
mucosa using protocol as described by Pikor et al. (2011). 
Extracted DNA was amplified using the 5 microsatellite 
primer sets for MSI markers Table 1) as outlined in the 
Bethesda panel. Tumor samples were classified as MSI-H, 
MSI-L and MSS accordingly. The forward primers were 
chemically labeled at 5’ end with fluorescent dyes. PCR 
was performed in a total volume of 20µl using 100ng of 
genomic DNA, 1X PCR buffer (Promega, Madison, WI, 
United States), 250µM each deoxynucleotide triphosphate 
(Thermo Fisher Scientific Inc.), 0.5µM each primer, 
1 unit of GoTaq polymerase (Promega, Madison, WI, 
United States) and 2.75nM MgCl2. PCR cycles for each 
marker were as in Table 2. Fluorescent PCR products 
were analyzed by capillary electrophoresis using an ABI 
3730xl DNA analyzer (Applied Biosystems) and Peak 
Scanner Software 2. 
Statistical analysis: Clinical data was collected 
using a retrospective chart review with a pre-designed 
and coded questionnaire. The Cox proportional hazard 
model was employed to compute prevalence ratios and 
95% confidence intervals. Significance was set at the P 
< 0.05 level.
Table 2. PCR conditions for MSI analysis
Marker Initial denaturation PCR cycles Final extension
BAT25 95° for 10 mins 35 cycle of 95°C for 1 min, 44°C for 1 min, 72°C for 1 min 72° for 10 mins
BAT26 95° for 10 mins 35 cycle of 95°C for 1 min, 42°C for 1 min, 72°C for 1 min 72° for 10 mins
D2S123 95° for 10 mins 35 cycle of 95°C for 45 s, 50°C for 45 s, 72°C for 45 s 72° for 10 mins
D5S346 95° for 10 mins 30 cycle of 95°C for 1 min, 44°C for 1 min, 72°C for 1 min 72° for 10 mins
D17S250 95° for 10 mins 35 cycle of 95°C for 45 s, 40°C for 45 s, 72°C for 45 s 72° for 10 mins
Table 1. PCR primers for MSI analysis
Marker Forward primer Reverse primer
BAT25 TCGCCTCCAAGAATGTAAGT TCTGGATTTTAACTATGGCTC
BAT26 TGACTACTTTTGACTTCAGCC AACCATTCAACATTTTTAACC
D2S123 AAACAGGATGCCTGCCTTTA GGACTTTCCACCTATGGGAC
D5S346 ACTCACTCTAGTGATAAATCGGG GCAGATAAGACAAGTATTACTAG
D17S250 GGAAGAATCAAATAGACAAT GCTGGCCATATATATATTTAAACC
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Results 
A cohort of 30 samples each was identified for the 
case (≤45 years at diagnosis) and control (>45 years at 
diagnosis) group (Table 3). The mean age at the time of 
diagnosis for the cases is 36.9 (range: 21-45) years and for 
controls is 63.7 (range: 47-85) years. A 3:1 male to female 
incidence ratio was observed in both cases and controls. 
Significantly more controls than cases had moderately 
differentiated tumors (P <0.001). No poorly differentiated 
tumors were found in controls as compared to 6 in the case 
cohort (P=0.005). Signet cell morphology was observed 
more in cases (16.6%) than controls (6.6%) (P=0.043). 
A significant proportion of cases had N2 nodal status as 
compared to controls. In cases and controls, the majority 
of patients had stage II and stage III disease at the time of 
diagnosis, however, more controls presented with stage 
I disease (P=0.03).
MSI was observed in 32 (53.3%) of the total patients 
with 19 (31.7%) classified as MSI-H and 13 (21.7%) 
as MSI-L tumors. Remaining 28 (46.7%) tumors were 
microsatellite stable. Equal numbers of cases (40% each) 
were MSI-H and MSS, while 53.3% of controls were 
designated as MSS tumors (Table 4). While more cases 
(40%) than controls (23.3%) were designated MSI-H, the 
difference was not statistically significant.
No differences were seen in major clinicopathological 
features and patient characteristics, including gender, 
tumor site, grade, morphology, nodal status and clinical 
stage, of cases and controls with respect to MSI status. The 
overall P value for each variable category (for e.g. nodal 
status) indicates that the differences were not statistically 
significant. Individual variables (for e.g. N0) also did not 
exhibit any statistically significant differences between 
cases and controls with respect to MSI status (data not 
shown).
Loss of MMR proteins (hMLH1, hMSH2 and/or 
HMSH6) was observed in all MSI tumors. MSI-H tumors 
more frequently showed loss of expression of these 
proteins than MSI-L tumors, irrespective of case or control 
cohort. Only 18.7% of MSS controls had loss of hMLH1 
expression. No other loss of MMR protein expression was 
seen in either MSS cases or controls. However, there were 
no significant differences between protein expression in 
cases and controls categorized by MSI status (Table 5).
The overal l  sensi t ivi ty and specif ici ty  of 
immunohistochemical analysis for detection of MSI 
colorectal cancers was 93.7% and 89.2% for cases and 
controls, respectively. Positive predictive value was 90.9% 
and negative predictive value was 92.5%. The overall 
accuracy was 91.6% (P=0.001).
Discussion
Colorectal cancers can be stratified into two groups 
on the basis of molecular aberrations. The first group 
includes tumors with chromosomal instability and the 
second tumors with microsatellite instability. MSI is 
more frequently observed in patients with Hereditary 
Non-polyposis Colorectal Cancer Syndrome (HNPCC) 
or Lynch syndrome. However, approximately 15 to 20% 
Table 3. Major clinicopathological features and patient 
characteristics of CRC cases and controls
Cases 
(n = 30)
Controls 
(n = 30)
P value
Average age 36.93 (21-45) 63.7 (47-85)
Gender
   Male 21 (70%) 24 (80%) 0.37
   Female 9 (30%) 6 (20%) 0.37
Site
   Left 18 (60%) 16 (53.3%) 0.53
   Right 12 (40%) 14 (46.6%) 0.46
Grade 
   Well 
differentiated 3 (10%) 1 (3.3%) 0.7
   Moderately 
differentiated 21 (70%) 29 (96.6%) <0.001*
   Poorly 
differentiated 6 (20%) 0 (0) 0.005*
   Signet ring 
morphology 5 (16.6%) 2 (6.6%) 0.043*
Nodal status
N0 15 (39.5%) 23 (60.5%) 0.06
N1 7 (58.3%) 5 (41.7%) 0.41
N2 7 (77.8%) 2 (22.2%) 0.017*
Nx 1 (100%) 0 (0%) -
Clinical stage
   I 1 (3.3%) 5 (16.6%) 0.03*
   II 15 (50%) 13 (43.3%) 0.61
   III 10 (33.3%) 8 (26.6%) 0.67
   IV 4 (13.3%) 3 (10%) 0.86
*Significant at the P < 0.05 level for 95% confidence interval
Table 4. Microsatellite status in CRC cases and controls
 Cases (n = 30) Controls (n = 30) P value
High (MSI-H) 12 (40.0%) 7 (23.3%) 0.16
Low (MSI-L) 6 (20.0%) 7 (23.3%) 0.75
Stable (MSS) 12 (40.0%) 16 (53.3%) 0.3
Table 5. Loss of mismatch repair protein expression 
with respect to microsatellite status in CRC cases and 
controls
Loss of MMR protein 
expression Overall 
P valuehMLH1 
(%)
hMSH2 
(%)
hMSH6 
(%)
MSI-H tumors 
0.21
   Case (n = 12) 9/12 (75) 10/12 
(83.3)
10/12 
(83.3)
   Control (n = 7) 6/7 
(85.7)
6/7 
(85.7)
6/7 
(85.7)
MSI-L tumors 
   Case (n = 6) 5/6 
(83.3)
2/6 
(27.7)
2/6 
(27.7)
   Control (n = 7) 3/7 
(42.8)
4/7 
(57.1)
5/7 
(71.4)
MSS tumors
   Case (n = 12) 0/12 (0) 0/12 (0) 0/12 (0)
   Control (n = 16) 3/16 
(18.7)
0/16 (0) 0/16 (0)
Sabeehuddin Siddique et al
Asian Pacific Journal of Cancer Prevention, Vol 17, 20162590
0
25.0
50.0
75.0
100.0
N
ew
ly
 d
ia
gn
os
ed
 w
ith
ou
t 
tr
ea
tm
en
t 
N
ew
ly
 d
ia
gn
os
ed
 w
ith
 t
re
at
m
en
t 
Pe
rs
is
te
nc
e 
or
 r
ec
ur
re
nc
e
Re
m
is
si
on
N
on
e
Ch
em
ot
he
ra
py
Ra
di
ot
he
ra
py
Co
nc
ur
re
nt
 c
he
m
or
ad
ia
tio
n
10.3
0
12.8
30.025.0
20.310.16.3
51.7
75.0
51.1
30.031.3
54.2
46.856.3
27.625.0
33.130.031.3
23.7
38.0
31.3
N
ew
ly
 d
ia
gn
os
ed
 w
ith
ou
t 
tr
ea
tm
en
t 
N
ew
ly
 d
ia
gn
os
ed
 w
ith
 t
re
at
m
en
t 
Pe
rs
is
te
nc
e 
or
 r
ec
ur
re
nc
e
Re
m
is
si
on
N
on
e
Ch
em
ot
he
ra
py
Ra
di
ot
he
ra
py
Co
nc
ur
re
nt
 c
he
m
or
ad
ia
tio
n
of sporadic CRC cases also demonstrate MSI.
Although the overall incidence of CRC is lower in 
developing countries, there is a significantly higher ratio 
of early onset to typical onset disease. Studies in the 
literature on Asian populations suggest that early onset 
CRC is a distinct entity characterized by presentation of 
advanced stage, poorly differentiated tumors, often found 
in the rectum. These characteristics have been reported 
in studies from India, Pakistan, Bangladesh, Nepal, 
Egypt, Jordan, Saudi Arabia, Morocco, Israel, Taiwan 
and Singapore (Singh et al., 2002; Al-Jaberi et al., 2003; 
Chiang et al., 2003; El-Hennawy et al., 2003;  Ahmed et 
al., 2005; Guraya and Eltinay, 2006; Chew et al., 2009; 
Gupta et al., 2010; Shemesh-Bar et al., 2010; Bhurgri et 
al., 2011; Amini et al., 2013; Sekal et al., 2015). We also 
found significantly more poorly differentiated tumors and 
fewer moderately differentiated tumors in early onset CRC 
patients as compared to typical onset. While the majority 
of early onset CRC patients in this study were categorized 
as stage II or III at the time of diagnosis, the same trend 
was also observed in typical onset CRC patients. In the 
sporadic cancer cohort reported here, a 3:1 male to female 
ratio was observed irrespective of the age at the time of 
diagnosis. This is considerably higher that global average 
of approximately 1:1, although some studies have reported 
a higher proportion of incidence in males as compared to 
females (Center et al., 2009; Haggar and Boushey, 2009). 
In the current study, this ratio may be due to the limited 
sample size, as we have previously reported a 2:1 male 
to female ratio in a larger CRC cohort (Zahir et al. 2014). 
This study aimed to determine the status of 
microsatellite instability and mismatch repair protein 
expression in sporadic early onset CRC as compared 
to typical onset CRC in the Pakistani population. We 
did not find any significant differences between the two 
groups. Earlier studies have reported variable results with 
respect to MSI in early onset CRCs, with early onset also 
inconsistently defined as age at diagnosis less than 40 – 
50 years. Gryfe et al. (2000) reported that 17% of early 
onset cases (defined as <50 years of age) were designated 
as MSI-H tumors. In another study, 29.4% patients less 
than 40 years of age demonstrated MSI compared to only 
6.3% patients of 60 years or more of age (Liang et al., 
2003). Giraldez et al. (2010) reported MSI in 11.4% of 
early onset (<50 years) cases. Other studies have found 
no MSI or MMR protein loss in sporadic, early onset 
CRC (Dieumegard et al., 2000; Magnani et al., 2015) or 
differences in MSI status in early onset CRC as compared 
to typical onset, including a study from India (Raman et 
al., 2014).
MSI status was correlated with clinicopathological 
features, including tumor site, grade, stage and histological 
type. MSI tumors have been previously associated with 
certain predictive and prognostic features (Saridaki et 
al., 2014; Phipps et al., 2015; Andersen et al., 2016; 
Gatalica et al., 2016). No significant differences were 
observed with regards to gender in early or typical 
onset CRC exhibiting MSI in accordance with earlier 
published reports (Raman et al., 2014). However, other 
studies have found that more females have MSI tumors 
(Moghbeli et al., 2011). MSI-H colorectal cancers are 
usually located in the right or proximal colon and have 
particular phenotypic characteristics, including poor 
differentiation, mucinous type, Crohn’s like lymphoid 
reaction and increased intraepithelial lymphocytes with 
an advanced clinical stage (Perea et al., 2010; Whitehall 
and Leggett, 2011; Michailidi et al., 2012; Kanth et al., 
2014; Musulén et al., 2014). Albasri et al. (2014) described 
a predominance of stage B and C tumors and tumors in 
rectosigmoid region in the Tunisian population. Moghbeli 
et al. (2011) reported that MSI tumors were mostly 
proximally located and associated with lower stage in 
the Iranian population. Similarly, Giraldez et al. (2010) 
found MMR deficiency in proximal, well to moderately 
differentiated tumors and Karahan et al. (2015) reported 
that loss of MMR protein expression is associated with 
proximal, poorly differentiated tumors and mucinous 
phenotype. In the study reported here, MSI-H tumors 
were found predominantly on the left side, but this was not 
statistically significant. In addition, MSI-H was found to 
be associated with both lower and higher staged colorectal 
tumors. Tumors with poor differentiation and mucinous 
features were not limited to MSI-H tumors, and were seen 
in MSI-L and MSS tumors in both early and typical onset 
CRCs. This is similar to another earlier study that did not 
find any significant differences in tumor differentiation 
and presence of mucinous type between the MSI and 
MSS early onset tumors (Perea et al., 2010). Supporting 
the results of our study, Ziadi et al. (2014) also did not 
find any significant differences in tumor location, nodal 
involvement and stage.
Studies reported in the literature have shown that 
mononucleotide repeat instability is more sensitive and 
specific for mismatch repair deficiency and recent studies 
have advocated the use of five mononucleotide repeats as 
markers of MSI. In this study, using the Bethesda panel 
of five markers, including two mononucleotide and three 
dinucleotide markers, we found that the dinucleotide 
markers performed better in detecting the MSI-H tumors 
in both early and typical onset CRCs. 
We also report high sensitivity and specificity of 
immunohistochemistry for MSI tumor detection. Previous 
studies have reported sensitivity ranging from 62%-89% 
for MSI detection (Hendriks et al., 2003; Shia et al., 
2005; Barnetson et al., 2006; Niessen et al., 2006). Loss 
of hMLH1 is usually observed in CRC in an older age 
group (Herman et al., 1998; Veigl et al., 1998; Cheah 
et al., 2014). In contrast, in our study, loss of hMLH1 
protein was frequently observed not only in typical onset 
CRC, but also in early onset CRC. Of note, a proportion 
of cases and controls in our study that showed loss of 
staining with hMLH1 antibody also had negative internal 
controls. Under such circumstances it is not possible to 
reliably comment on the mismatch enzyme deficiency. 
This is a drawback with immunohistochemical analysis 
for MMR, a fact that has been highlighted previously in 
a multicenter study (Müller et al., 2001). Furthermore, 
hMLH1 has a very low sensitivity (74%) due to a low rate 
of detection (Shia, 2008). Since hMLH1 forms dimers with 
hPMS2 and hMSH2 dimerizes with hMSH6, loss of these 
proteins usually occur in pairs. We found isolated loss of 
hMSH2 without loss of hMSH6 in both early and typical 
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onset CRCs, which has been reported previously in the 
literature (Giraldez et al., 2010; Ziadi et al., 2014). The 
cause for this observation needs to be evaluated further. 
However, it could be due to the fact that while there are 
mutations in the mismatch repair enzymes in MSI tumors, 
the expressed proteins still retain their antigenicity and 
react with the respective antibody giving false positive 
results. We also observed loss of expression of hMLH1 
in three MSS tumors from the control typical onset CRC 
group.  Giraldez et al. (2010) have similarly reported loss 
of hMLH1 and hMSH6 in MSS tumors.
Sample size was a limitation of this retrospective study 
due to availability of tissue samples. Another limitation 
is that we only investigated loss of hMLH1, hMSH2 and 
hMSH6 expression for mismatch repair. Even though 
isolated loss of hPMS2 is rarely reported (Gill et al., 2005; 
Mojtahed et al., 2011; Cheah et al., 2014), a lower hMLH1 
immunohistochemistry sensitivity may necessitate hPMS2 
detection.
In conclusion, although early onset sporadic colorectal 
cancer has been studied previously, there have been very 
few studies that have compared it to typical onset sporadic 
disease. In addition, molecular differences have not been 
previously profiled in the Pakistani population. In this 
study, we have shown that early onset sporadic CRCs 
present significantly with more poorly differentiated 
tumors, N2 nodal involvement and higher frequency of 
signet ring phenotype than typical onset sporadic CRC 
patients. Microsatellite instability and MMR protein 
expression patterns were similar in both early onset 
and typical onset sporadic CRCs and no significant 
clinicopathological differences were correlated with MSI 
status. This indicates that the comparative histological 
tumor profile observed in the early onset cohort could be 
a result of molecular features other than microsatellite 
instability. Future studies are needed to identify role of 
other molecular mechanisms in this population, such as 
chromosomal instability and the mutator phenotype, to 
identify causative and mechanistic differences between 
early onset and typical onset sporadic disease. Mutational 
profiling of frequently mutated genes in CRC may also 
provide further insight into the increased incidence of 
early onset colorectal cancers in Pakistan. 
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